Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at accelerating the development of digital therapeutics (DTx) to treat substance use disorders (SUDs). This initiative seeks to support the creation of clinical-grade mobile, web, or software-based platforms that are safe and effective for SUD treatment, with a focus on obtaining FDA authorization for these interventions. The funding follows a two-phase structure, with the UG3 phase allowing for up to two years of initial development and milestone achievement, and the UH3 phase extending up to three years based on successful progression, with no budget limit for the latter phase and a cap of $500,000 for the UG3 phase. Interested applicants, including various educational institutions and organizations, must submit their proposals by February 26, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.